Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate
Journal of Clinical Oncology2005Vol. 23(17), pp. 3948–3956
Citations Over TimeTop 1% of 2005 papers
Jean‐Pierre J. Issa, Vazganush Gharibyan, Jörge E. Cortes, Jaroslav Jelı́nek, Gail Morris, Srđan Verstovšek, Moshe Talpaz, Guillermo Garcia‐Manero, Hagop M. Kantarjian
Abstract
Decitabine induces hypomethylation and has clinical activity in imatinib refractory chronic myelogenous leukemia. We hypothesize that the inverse correlation between hypomethylation 2 weeks after therapy and response is due to a cell death mechanism of response, whereby resistant cells can withstand more hypomethylation.
Related Papers
- → Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia(2005)68 cited
- → Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia(2009)9 cited
- → Management of chronic myelogenous leukemia using therapeutic drug monitoring of imatinib: the French experience of a centralized laboratory(2008)2 cited
- → New Agents in Chronic Myelogenous Leukemia(2003)
- Clinical observation on the effects of low dosage imatinib to chronic myelogenous leukemia in blast crisis(2004)